Timing of postoperative chemoradiotherapy and survival outcomes in high-risk locally advanced head and neck squamous cell carcinoma: A supplementary analysis of JCOG1008.
Abstract
6015 Background: For patients with post-operative high-risk locally advanced head and neck squamous cell carcinoma (LA-HNSCC), initiation of chemoradiotherapy (CRT) within 6 weeks after surgical resection is recommended based on previous reports. However, the guideline-defined 6-week threshold for initiating post-operative radiotherapy (PORT) is derived mainly from data in patients treated with PORT alone. Therefore, its relevance in patients receiving post-operative CRT remains uncertain. Methods: This supplementary analysis used data from the JCOG1008 trial (jRCTs031180135), which compared post-operative CRT with weekly cisplatin versus 3-weekly cisplatin. Associations between the surgical-to-PORT interval (S-PORT) and locoregional relapse-free survival (LRFS), overall survival (OS), and relapse-free survival (RFS) were evaluated using restricted cubic spline analyses, Kaplan–Meier methods, and Cox proportional hazards models. Treatment package time (TPT), defined as the sum of S-PORT and radiotherapy duration, was also assessed. Results: Among 261 enrolled patients, 251 were eligible for this analysis (median age, 62 years; 16.3% female; 45.8% with oral cavity primaries). The median S-PORT and TPT were 7.0 weeks (range, 2.9–10.0) and 13.9 weeks (range, 7.6–16.9), respectively. Restricted cubic spline analyses demonstrated minimal variation in risk across the observed S-PORT range, with hazard ratios (HRs) remaining close to 1 for LRFS, OS, and RFS. Kaplan–Meier analyses using the guideline-defined 6-week cutoff showed similar 5-year LRFS between patients with S-PORT ≤6 weeks and >6 weeks (64.0% vs 64.9%; HR 0.91, 95% CI 0.60–1.37; Table), with no significant differences in OS or RFS. In multivariable Cox models adjusting for clinical covariates, S-PORT was not independently associated with outcomes. Findings for TPT closely paralleled those for S-PORT, with no significant associations observed between TPT and treatment. Conclusions: In this supplementary analysis of JCOG1008, no prognostic disadvantage was observed when PORT was initiated within the range observed in this trial (6–10 weeks after surgery) among patients receiving post-operative CRT. These findings support individualized S-PORT timing rather than rigid cutoff-based decision-making in contemporary standardized CRT. Clinical trial information: jRCTs031180135. Kaplan–Meier analyses according to guideline-defined 6-week surgical-to-postoperative radiotherapy interval (S-PORT) cutoff. S-PORT ≤ 6 weeks S-PORT > 6 weeks 5y LRFS (95% CI) 64.0% (52.1%–73.7%) 64.9% (57.3%–71.5%) HR (95% CI), p-value 1 0.91 (0.60–1.37), 0.65 5y OS (95% CI) 65.3% (53.4%–74.9%) 66.6% (59.1%–73.1%) HR (95% CI), p-value 1 0.88 (0.58–1.34), 0.54 5y RFS (95% CI) 60.0% (48.0%–70.1%) 60.2% (52.6%–67.0%) HR (95% CI), p-value 1 0.98 (0.66–1.46), 0.93
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (20)
Yoshinori Imamura
Kobe University Hospital, Kobe, Japan
Naomi Kiyota
Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Hyogo, Japan
Koichi Yasuda
Takeshi Kodaira
Aichi Cancer Center Hospital, Nagoya, Japan
Hiroshi Nishino
Yukinori Asada
Hiroki Mitani
Yuji Hirayama
Hyogo Cancer Center, Akashi, Japan
Naoki Nishio
Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Aichi, Japan
Yusuke Onozawa
Shizuoka Cancer Center, Shizuoka, Japan
Nobuhiro Hanai
Aichi Cancer Center Hospital, Nagoya, Japan
Akira Ohkoshi
Department of Otolaryngology—Head and Neck Surgery, Tohoku University Graduate School of Medicine, Miyagi, Japan
Nobuya Monden
NHO Shikoku Cancer Center, Matsuyama, Japan
Masato Nagaoka
Department of Otorhinolaryngology—Head and Neck Surgery, Jikei University School of Medicine, Tokyo, Japan
Shujiro Minami
NHO Tokyo Medical Center, Tokyo, Japan
Kaoru Tanaka
Kindai University Hospital, Sakai, Japan
Takashi Fujii
Department of Electrical and Electronic Engineering, Ritsumeikan University 2 , 1-1-1 Noji-Higashi, Kusatsu, Shiga 525-8577,
Yuya Ishikawa
Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
Tetsuya Sekita
Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
Makoto Tahara